Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Jun 28 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received tentative approval from the USFDA for Palbociclib Tablets in various dosages. Palbociclib is indicated for treating a specific type of breast cancer and will be produced at the company's facility in Ahmedabad. The press release highlights that the product had significant annual sales in the United States, indicating its market potential.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated Jun 28, 2023, titled "Zydus receives tentative approval from the USFDA for Palbociclib Tablets, 75 mg, 100 mg, and 125 mg".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases